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Changes in GABAergic inhibition occur during physiological processes, during response
to drugs and in various pathologies. These changes can be achieved through
direct allosteric modifications at the γ-amino butyric acid (GABA) type A (GABAA)
receptor protein level, or by altering the synthesis, trafficking and stability of the
receptor. Neurosteroids (NSs) and protein kinase C (PKC) are potent modulators of
GABAA receptors and their effects are presumably intermingled, even though evidence
for this hypothesis is only partially explored. However, several PKC isoforms are
able to phosphorylate the GABAA receptor, producing different functional effects.
We focused on the ε isoform, that has been correlated to the sensitivity of the
GABAA receptor to allosteric modulators and whose expression may be regulated in
peripheral sensory neurons by NSs. The cross-talk between PKC-ε and NSs, leading
to changes in GABAA receptor functionality, is considered and discussed in this
perspective.
Keywords: GABAA receptor, phosphorylation site, neurosteroids, receptor traffiking, PKCepsilon
Introduction
GABAA receptors are fundamental for fast synaptic inhibition in the brain. Given the role
of these receptors in synaptic transmission, all the mechanisms that regulate their activity
are of primary importance. One that is particularly significant is receptor phosphorylation.
Kinases represent a superfamily of isoenzymes that, through protein phosphorylation, regulate
several cellular processes, including proliferation, differentiation, tumorigenesis, cytoskeletal
remodeling, receptor function and synaptic transmission modulation (Battaini, 2001). This
superfamily comprises the protein kinase (PK) A, G and C, which are serine/threonine
phosphotransferases.
Protein kinase C (PKC) is one of the most significant kinases for GABAA receptor modulation.
Phosphorylation of the receptor can produce different effects, ranging from enhancement to
inhibition of protein function, depending on the subtype of subunit targeted and on the location of
the sites being phosphorylated (Moss and Smart, 1996).
In particular, among PKC enzymes there are conventional (α, βI, βII and Υ) and new
(δ, ε, η and θ) isoforms (Nishizuka, 1995), that are differently expressed in the nervous system.
The differences among PKC isoforms contribute to the large range of functions they may
perform.
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Some PKCs directly bind to the intracellular domain of
specific GABAA receptor subunits, providing in this way a rapid
regulation of the receptor activity by all the intracellular pathways
that activate this kinase (Brandon et al., 1999).
PKC-Epsilon (PKC-ε)
PKC-ε is classified as a novel isoform present in the brain, found
mainly in the cerebral cortex, cerebellum, hippocampus and, in
small amount, in non-nervous peripheral tissues (Saito et al.,
1993; Chen et al., 2000).
The characterization of PKC-ε null mice has provided
insights into the role of PKC-ε in the central nervous system
(CNS; Hodge et al., 1999). Animals lacking PKC-ε show
hypersensitivity to the behavioral effects of allosteric modulators
of GABAA receptors, such as ethanol and neurosteroids
(NSs; Hodge et al., 2002). Among NSs, the progesterone
metabolite Allopregnanolone (Allo) is one of the most important
endogenous steroid in the CNS (Baulieu and Robel, 1990), as
changes in its concentration correlate with physiological and
pathological conditions(Maguire andMody, 2007; Luchetti et al.,
2011).
In vitro studies on cortical synaptosomes demonstrate that
a peptide able to inhibit PKC-ε translocation (Khasar et al.,
1999) produces an increase in Allo sensitivity (Hodge et al.,
1999). Similarly, in primary cultures of cortical neurons Allo
is more effective in potentiating GABA-evoked current when
the cells are intracellularly perfused with this same inhibitory
peptide (Figure 1A). From analysis of the dose-response curves
of this Allo effect, it is evident that the potency of NSs
remains unchanged after blocking PKC-ε translocation, whereas
the efficacy is increased (Figure 1B). We cannot determine
whether the receptors mediating the increased response to
Allo were at synaptic or extrasynaptic sites. However, it is
possible that a selective phosphorylation by PKC-ε occurs, in
this case the kinase activity determines selective changes only
in synaptic or in tonic currents. The use of a heterologous
system, expressing different GABAA receptor subunits, or
specific agonists for ‘‘tonic receptors’’ could provide the answer
to this issue.
Recent studies showed that PKC-ε action depends on the
phosphorylation of the GABAA receptor at the level of Ser327
of the γ2 subunit (Qi et al., 2007), in turn regulating the
response of the receptors to allosteric modulators. Furthermore,
PKC-ε kinase controls GABAA receptor trafficking through the
N-Ethylmaleimide-Sensitive Factor (NESF)-signaling pathway.
Indeed, as suggested by the changes in Allo efficacy from in
vitro studies (Figure 1B), the activation of PKC-ε is able to
decrease cell surface expression of these receptors (Chou et al.,
2010).
NSs and Phosphorylation
Allo, and other NSs that are positive modulators of GABAA
receptors, potentiate GABA-evoked chloride current through an
increase in the channel opening probability (Puia et al., 1990;
Twyman and Macdonald, 1992; Zhu and Vicini, 1997). This
results in a prolongation in the decay time of inhibitory post-
synaptic currents (IPSCs; Harrison et al., 1987; Fáncsik et al.,
2000). However, NSs also act on extrasynaptic GABAA receptors,
causing large effects on δ-containing receptors that mediate the
tonic current in certain brain regions (Belelli et al., 2002; Stell
et al., 2003).
Interestingly, the desensitization of GABAA receptors plays
an important role in NSs’ modulation (Zhu and Vicini, 1997),
suggesting that the receptor needs to be in a ‘‘specific’’ state to be
responsive to these endogenous NSs.
Furthermore, NSs produce long-lasting changes in the
efficacy of GABAergic neurotransmission by modulating
the phosphorylation of synaptic and extrasynaptic receptors.
Indeed, in a recent paper, Abramian et al. showed a new
molecular mechanism by which NSs change the efficacy of
GABAergic inhibition by increasing surface expression of
specific GABAA receptors (mainly containing α4 subunits),
responsible for the tonic current in hippocampus (Abramian
et al., 2014). They suggested that this component of GABAergic
neurotransmission may be a key regulator of excitability. In this
way the phosphorylation process may alter the function and/or
trafficking of GABAA receptors, thus changing the efficacy of
GABAA-mediated inhibition.
Interestingly other allosteric modulators of GABAA
receptors, i.e., benzodiazepine, may also change GABA
signaling, influencing the diffusion and clustering of receptors
at synapses (Lévi et al., 2015). Conversely, it was shown
that the potentiating effect of NSs can be decreased after
stimulation of the PKC signaling pathway, either in physiological
(Brussaard et al., 2000; Brussaard and Koksma, 2003;
Maguire et al., 2005; Oberlander et al., 2012) or pathological
conditions (Mtchedlishvili et al., 2001; Kia et al., 2011). For
example, the phosphorylation state of the GABAA receptor
changes during pregnancy or over the estrous cycle, a
phenomenon that can compromise GABAA modulation by
NS action.
The modulatory efficacy of NSs is decreased in dentate
granule cells from epileptic rats (Mtchedlishvili et al., 2001).
This agrees with the observation that brain and cell specific
changes in GABAA receptors may occur in several epileptic
models (Schwarzer et al., 1997; Fritschy et al., 1999; Peng et al.,
2004) and in the temporal lobe of human epileptic subjects
(Loup et al., 2000; Ferando and Mody, 2012). Recent studies
show changes in the phosphorylation of GABAA receptors
after kindling; these modifications together with changes in
GABAA subunit composition could account for a decreased
responsiveness to NSs (Kia et al., 2011; Carver et al., 2014).
The diminished sensitivity to endogenous positive allosteric
modulators, such as Allo, increases susceptibility to seizures,
similarly to what happens in women with catamenial epilepsy,
where seizures occur more frequently before the onset of
menses and NS levels fall due to progesterone crash (Reddy,
2009).
Also important is the cross-talk among PKC-ε, GABAA
receptors and NSs in pain perception. NS production is
stimulated as a result of inflammatory pain (Poisbeau et al.,
2005), and accordingly changes in PKC-ε expression were
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FIGURE 1 | (A) Electrophysiological traces showing the effect of Allo on
GABA-evoked currents recorded from cortical neurons in culture (7DIV). The
upper trace shows a recording from a control cell (red) and the lower trace is
from a cell intracellularly perfused with the peptide εV1--2, a PKC-ε inhibitor.
(B) Dose response curves of Allo effect in control and in the presence of the
peptide eV1--2. Each point is the mean+/−SE of 8--15 cells. PKC-ε blockade
did not change the potency of Allo but affected its efficacy. (C) Assessment of
PKC-ε gene expression changes (as fold changes) in primary culture of dorsal
root ganglia (DRG) neuron after 24 h exposure to 10−6 M Allo (white column), or
to the culture conditioned medium obtained from Schwann cell cultures treated
with 10−6 M Allo (gray column). The relative quantification of mRNA was
obtained by quantitative real time PCR. Data were normalized to the
housekeeping genes α-tubulin and β2-microglobulin and expressed as
difference (∆∆Ct) vs. controls, then averaged for each experimental group. The
black column represents the controls (DRG neurons treated with vehicle,
ethanol). Experiments were repeated at least three times (*p < 0.05 Anova Test).
observed during pathological pain (Parada et al., 2003).
Vergnano et al. proposed that the 3α-5α-NSs (such as Allo)
could be part of an endogenous compensatory mechanism, in
response to sustained activation of the spinal nociceptive system
that occurs during pathological conditions (Vergnano et al.,
2007).
The persistence of incoming painmessages, and the associated
increases in intracellular Ca2+ concentration, could induce
a strong stimulation of Ca2+-dependent PKC. This leads
to a functional block of GABAA receptors in their current
state. Therefore, PKC prevents further 3α-5α-NS dependent
potentiation, without decreasing the basal modulatory effect of
3α-5α-NSs (Vergnano et al., 2007).
PKC-ε exerts a modulatory action on the pain pathways
acting on CNS neurons, but also at the peripheral nervous
system (PNS) level, for instance on dorsal root ganglia
(DRG) neurons. Indeed, PKC-ε may alter the permeability of
Na-type Ca2+ channels in DRG, and it has been shown to
enhance nociception (Van Kolen et al., 2008). The capability
of endogenous mediators to regulate PKC-ε gene expression
has already been demonstrated for several molecules, including
the neuropeptide ghrelin, thyroid hormones, the apolipoprotein
E3 and some miRNAs (Rybin and Steinberg, 1996; Alipour
et al., 2011; Sen et al., 2012). However, no data reported
on the possible modulation exerted by NSs on PKC-ε gene
expression. Recent studies by qRT-PCR analysis evaluated the
possible modulation of PKC-ε expression in DRG neuronal
cultures following 24-h treatment with Allo (10−6 M). Allo
did not change PKC-ε expression under basal conditions, but
was significantly upregulated in DRG neurons exposed to the
culture medium from Allo-treated Schwann cells (Figure 1C).
These findings suggest that Allo-treated Schwann cells can
release one or more factors able to modulate PKC-ε expression
in DRG neurons. However, Schwann cells also express basal
levels of PKC-ε (Borghini et al., 1994). Overall, we speculate
that these mechanisms identify novel putative circuits involved
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 March 2015 | Volume 9 | Article 83
Puia et al. Phosphorylation and neurosteroids
FIGURE 2 | Schematic plot of the possible cross-talks among PKC-ε, Allopregnanolone and GABAA receptors.
in the regulation of pain processes at PNS and spinal cord
levels.
Given that Allo is considered one key factor in themodulation
of peripheral pain pathways, its capability to regulate PKC-ε is
promising and opens new perspectives for the identification of
the basic mechanisms regulating chronic pain onset.
Conclusions
The activity of GABAA receptors must be finely regulated
in the CNS. For this reason when NSs increase GABAA
receptor activity, the ‘‘system’’ tries to re-equilibrate by
activating different PKs. The increase in neuronal activity
that occurs by activating L-type Ca2+ channels leads to a
Ca2+/calmodulin-dependent PK type II phosphorylation of the
GABAA receptor β3 subunit. This in turn produces a rapid
insertion of receptors in the membrane, with a consequent
increase in tonic current (Saliba et al., 2012). Similarly, NSs
promote GABAA receptor phosphorylation, leading to an
increase in extrasynaptic receptor expression (Abramian et al.,
2014).
These findings shed light on a new type of modulatory
activity played by NSs. Indeed, NSs not only allosterically
modulate GABAA receptor function and synthesis, but can
also regulate membrane trafficking of the receptor protein,
which is particularly important in determining synapse efficacy.
Another NS, pregnenolone sulphate, uses the same ‘‘strategy’’
to modulate N-Methyl-D-aspartate (NMDA) receptor-mediated
neurotransmission. Indeed, its effects are determined by direct
modulation of the NMDA receptor, but also by increasing
receptor expression on the cell surface (Kostakis et al.,
2013).
Interestingly, in physio-pathological situations, or after
pharmacological treatments, NSs (endogenous and exogenous)
and PKC activities may vary a lot. The precise role of functional
cross-talk between these ‘‘modulators’’ (Adams et al., 2015) and
how these interactions can affect GABAA receptor function are
still a matter of investigation.
In Figure 2 we summarize some of the interrelationships
among these three players. We believe that it is important
to keep in mind these pathways. Eventually, shedding
light on other presently unknown cross-talks will help
to better understand the mechanisms underlying some
neuropathologies, as well as unraveling the mechanisms
of action of novel GABAA modulating drugs. However,
a complex picture emerges from the recent findings. The
pharmacological response to endogenous molecules or to
exogenous drugs results from the dynamic interrelationship
between modulators and receptor proteins. This cross-talk
can produce different responses, depending on factors such as
cellular distribution or subtype and phosphorylation state of the
receptor involved.
As a general perspective, the importance of GABAA
receptor phosphorylation is particularly relevant when a
pharmacological treatment involving allosteric GABAA receptor
modulators, such as NSs, is started. However, it should
be emphasized that GABAA receptor rearrangement at the
synapse level, and/or changes in receptor subunit composition,
can lead to different pharmacological effects. Altogether,
these hypotheses should be taken into account to better
understand the complex behavior of NSs at the level of
neuronal circuitries (Puia et al., 2012) and in in vivo
studies.
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